Literature DB >> 25194144

Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration.

Josep Franch-Nadal1, Pilar Roura-Olmeda2, Belén Benito-Badorrey3, Antonio Rodriguez-Poncelas4, Gabriel Coll-de-Tuero5, Manel Mata-Cases6.   

Abstract

BACKGROUND: Control of glycaemic levels as well as cardiovascular risk factors (CVRF) is essential to prevent the onset of complications associated with type 2 diabetes mellitus (T2DM). AIM: To describe the degree of glycaemic control and CVRF in relation to diabetes duration. PATIENTS AND METHODS: Multicentre cross-sectional study in T2DM patients seen in primary care centres during 2007. VARIABLES: Demographical and clinical characteristics, antidiabetic treatments and development of disease complications. Diabetes duration classification: 0-5, 6-10, 11-20 and >20 years. Logistic regression models were used in the analysis.
RESULTS: A total of 3130 patients; 51.5% males; mean age: 68±11.7 years; mean diabetes duration:7.0 (±5.6) years, median: 5 (interquartile range:3-9) years; mean HbA1c: 6.84 (±1.5), were analyzed. There has been a progressive decline in HbA1c levels (HbA1c > 7% in 25.8% of patients during the first 5 years and 51.8% after 20 years). Blood pressure values remained relatively stable throughout disease duration. The mean value of low density lipoprotein (LDL) experienced a slight decline with the progression of the disease, but due to the significant increase of cardiovascular disease (CVD) after 20 years of duration, less patients reached the recommended target (LDL < 100mg/dl) in secondary prevention. Logistic regression model controlling for age, sex and CVD showed that diabetes duration was related to glycaemic control (odds ratio: 1.066, 95% confidence interval: 1.050-1.082 per year) but not to blood pressure or LDL control.
CONCLUSIONS: The degree of glycaemic control and the risk factors in relation to the duration of T2DM followed different patterns. Diabetes duration was associated with a poorer glycaemic control but in general had a limited role in blood pressure control or lipid profile.
© The Author 2014. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiovascular risk factors; T2DM.; control; disease duration

Mesh:

Substances:

Year:  2014        PMID: 25194144     DOI: 10.1093/fampra/cmu048

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  9 in total

1.  Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes.

Authors:  Mitsuyoshi Takahara; Toshihiko Shiraiwa; Taka-Aki Matsuoka; Kaoru Yamamoto; Yoshifumi Maeno; Yuka Shiraiwa; Yoko Yoshida; Naoto Katakami; Hiroaki Iijima; Hideyuki Katsumata; Kenji Arakawa; Toshio Hashimoto; Iichiro Shimomura
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-18       Impact factor: 3.168

2.  Quality of diabetes care at the largest outpatient clinics in Vilnius.

Authors:  Žydrūnė Visockienė; Laura Šiaulienė; Roma Puronaitė; Virginijus Šapoka; Vytautas Kasiulevičius
Journal:  Acta Med Litu       Date:  2016

3.  Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study.

Authors:  Anna G Nilsson; Ragnhildur Bergthorsdottir; Pia Burman; Per Dahlqvist; Bertil Ekman; Britt Edén Engström; Oskar Ragnarsson; Stanko Skrtic; Jeanette Wahlberg; Heinrich Achenbach; Sharif Uddin; Claudio Marelli; Gudmundur Johannsson
Journal:  Eur J Endocrinol       Date:  2017-03-14       Impact factor: 6.664

4.  Duration of diabetes and types of diabetes therapy in Japanese patients with type 2 diabetes: The Japan Diabetes Complication and its Prevention prospective study 3 (JDCP study 3).

Authors:  Yasuaki Hayashino; Kazuo Izumi; Shintaro Okamura; Rimei Nishimura; Hideki Origasa; Naoko Tajima
Journal:  J Diabetes Investig       Date:  2016-08-10       Impact factor: 4.232

5.  Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats.

Authors:  Yuzhen Jia; Binger Xu; Jisen Xu
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

6.  Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study.

Authors:  Norihiro Kuroda; Yoshiki Kusunoki; Keiko Osugi; Mana Ohigashi; Daisuke Azuma; Hiroki Ikeda; Shinya Makino; Akihito Otsuka; Daisuke Tamada; Nobuaki Watanabe; Kahori Washio; Taku Tsunoda; Toshihiro Matsuo; Kosuke Konishi; Tomoyuki Katsuno; Hidenori Koyama
Journal:  J Diabetes Investig       Date:  2020-08-02       Impact factor: 4.232

Review 7.  Population segmentation of type 2 diabetes mellitus patients and its clinical applications - a scoping review.

Authors:  Jun Jie Benjamin Seng; Amelia Yuting Monteiro; Yu Heng Kwan; Sueziani Binte Zainudin; Chuen Seng Tan; Julian Thumboo; Lian Leng Low
Journal:  BMC Med Res Methodol       Date:  2021-03-11       Impact factor: 4.615

8.  Effects of a Digital Patient Empowerment and Communication Tool on Metabolic Control in People With Type 2 Diabetes: The DeMpower Multicenter Ambispective Study.

Authors:  Domingo Orozco-Beltrán; Cristóbal Morales; Sara Artola-Menéndez; Carlos Brotons; Sara Carrascosa; Cintia González; Óscar Baro; Alberto Aliaga; Karine Ferreira de Campos; María Villarejo; Carlos Hurtado; Carolina Álvarez-Ortega; Antón Gómez-García; Marta Cedenilla; Gonzalo Fernández
Journal:  JMIR Diabetes       Date:  2022-10-03

9.  Effectiveness of standardized nursing care plans to achieve A1C, blood pressure, and LDL-C goals among people with poorly controlled type 2 diabetes mellitus at baseline: four-year follow-up study.

Authors:  J Cárdenas-Valladolid; A López-de Andrés; R Jiménez-García; M J de Dios-Duarte; P Gómez-Campelo; C de Burgos-Lunar; F J San Andrés-Rebollo; J C Abánades-Herranz; M A Salinero-Fort
Journal:  BMC Fam Pract       Date:  2018-07-24       Impact factor: 2.497

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.